Compare Costco Wholesale Corporation (COST) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Costco Wholesale Corporation vs Summit Therapeutics Inc — how do they compare? Costco Wholesale Corporation trades at $946.92 (market cap $420.05B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Costco Wholesale Corporation is far larger — about 30.6× Summit Therapeutics Inc's market cap, and Costco Wholesale Corporation pays a 0.62% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Costco Wholesale Corporation for 133 Days and Summit Therapeutics Inc for 16 Days on average.
| COST | SMMT | |
|---|---|---|
Market Cap | $420.05B | $13.71B |
Volume | 2,087,565 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $1.09K | $26.38 |
52-Week Low | $849.63 | $12.43 |
Typical Hold Time | 133 Days | 16 Days |
Enterprise Value | $407.33B | $13.04B |
Dividend Yield | 0.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Costco (COST) trades at $947.92, up 0.6% on the day, near its pivot point of $947 with strong analyst consensus. The stock shows bullish moving averages but overbought RSI signals. Recent March sales surged 11.3% year-over-year to $28.41 billion (Costco report, April 8, 2026), while Q2 2026 EPS beat expectations. Valuation remains elevated with a P/E of 45.66, supported by robust membership fee growth and expansion.
Outlook is positive given consistent revenue growth and high renewal rates post-fee hike, but risks include premium valuation sensitivity and competitive pressures. The consensus price target of $1,100 implies ~16% upside, with institutional buying underscoring confidence. Key catalysts are Q3 2026 earnings and sustained comp sales momentum.
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Costco Wholesale Corporation
The leading warehouse club, Costco has 815 stores worldwide (at the end of fiscal 2021), with most sales derived in the United States (72%) and Canada (14%). It sells memberships that allow customers to shop in its warehouses, which feature low prices on a limited product assortment. Costco mainly caters to individual shoppers, but roughly 20% of paid members carry business memberships. Food and sundries accounted for 40% of fiscal 2021 sales, with non-food merchandise 29%, warehouse ancillary and other businesses (such as fuel and pharmacy) nearly 17%, and fresh food 14%. Costco's warehouses average around 146,000 square feet
Read more on COST →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
